



# ORAL ONCOLOGY REFERRAL FORM

580 N. Main Street • Barnegat, NJ 08005  
Phone: 609-660-1111 • Fax: 609-660-0101

Today's Date \_\_\_\_\_  
 CURRENT PATIENT  
 NEW PATIENT

Patient Name \_\_\_\_\_ Date of Birth \_\_\_\_\_  
 Male  Female SS# \_\_\_\_\_ Language \_\_\_\_\_  
Address \_\_\_\_\_ Apt # \_\_\_\_\_  
City \_\_\_\_\_ State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_ Cell \_\_\_\_\_ Email \_\_\_\_\_  
Allergies \_\_\_\_\_  
Ship to Patient at  Home  Work  
OR Patient will pick up at  Jersey Shore Pharmacy  Physician Office

Insured's Name \_\_\_\_\_  
Relation to Patient \_\_\_\_\_  
Eligible for Medicare?  Yes  No If yes, Medicare# \_\_\_\_\_  
Prescription Card  Yes  No If Yes, Carrier \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_  
Policy/Group# \_\_\_\_\_  
Bin# \_\_\_\_\_ Pcn# \_\_\_\_\_  
RXID# \_\_\_\_\_ RX Group# \_\_\_\_\_

ICD-10 Code \_\_\_\_\_ Diagnosis \_\_\_\_\_ Cancer Stage:  Stage 0  Stage I  Stage II  Stage III  Stage IV  Other \_\_\_\_\_  
Has patient been treated previously for this condition?  Yes  No Medications: \_\_\_\_\_  
Is patient currently on therapy?  Yes  No Medications: \_\_\_\_\_  
Will patient stop taking the above medication(s) before starting the new medication?  Yes  No If yes, what is the washout period? \_\_\_\_\_  
Other medications patient is currently taking including OTC medications with dosage and direction (or fax medication profile): \_\_\_\_\_

## PRESCRIPTION

## PLEASE ATTACH COPIES OF PATIENT'S INSURANCE CARDS

<input type="checkbox"/> <b>AFINITOR</b>	<input type="checkbox"/> 2.5 mg tab	<input type="checkbox"/> 5 mg tab	
	<input type="checkbox"/> 7.5 mg tab	<input type="checkbox"/> 10 mg tab	
<input type="checkbox"/> <b>BOSULIF</b>	<input type="checkbox"/> 100 mg tab	<input type="checkbox"/> 500 mg tab	
<input type="checkbox"/> <b>GLEEVEC</b>	<input type="checkbox"/> 100 mg tab	<input type="checkbox"/> 400 mg tab	
<small>(will dispense combination of 100 mg and 400 mg tab based on patient's dose)</small>			
<input type="checkbox"/> <b>HYCAMTINE</b>	<input type="checkbox"/> 0.25 mg tab	<input type="checkbox"/> 1 mg tab	
<input type="checkbox"/> <b>INLYTA</b>	<input type="checkbox"/> 1 mg tab	<input type="checkbox"/> 5 mg tab	
<small>(will dispense combination of 1 mg and 5 mg tab based on patient's dose)</small>			
<input type="checkbox"/> <b>MEKINIST</b>	<input type="checkbox"/> 0.5 mg tab	<input type="checkbox"/> 1 mg tab	<input type="checkbox"/> 2 mg tab
<input type="checkbox"/> <b>NEXAVAR</b>	<input type="checkbox"/> 200 mg tab		
<input type="checkbox"/> <b>NINLARO</b>	<input type="checkbox"/> 2.3 mg cap	<input type="checkbox"/> 3 mg cap	<input type="checkbox"/> 4 mg cap
<input type="checkbox"/> <b>PROMACTA</b>	<input type="checkbox"/> 12.5 mg tab	<input type="checkbox"/> 25 mg tab	<input type="checkbox"/> 50 mg tab
	<input type="checkbox"/> 75 mg tab	<input type="checkbox"/> 100 mg tab	
<input type="checkbox"/> <b>SPRYCEL</b>	<input type="checkbox"/> 20 mg tab	<input type="checkbox"/> 50 mg tab	<input type="checkbox"/> 70 mg tab
	<input type="checkbox"/> 80 mg tab	<input type="checkbox"/> 100 mg tab	<input type="checkbox"/> 140 mg tab
<input type="checkbox"/> <b>STIVARGA</b>	<input type="checkbox"/> 40 mg tab		
<input type="checkbox"/> <b>SUTENT</b>	<input type="checkbox"/> 12.5 mg cap	<input type="checkbox"/> 25 mg cap	<input type="checkbox"/> 50 mg cap
	<input type="checkbox"/> 50 mg po daily for 4 weeks on and 2 weeks off		

<input type="checkbox"/> <b>TAFINLAR</b>	<input type="checkbox"/> 50 mg cap	<input type="checkbox"/> 75 mg cap	
<input type="checkbox"/> <b>TARCEVA</b>	<input type="checkbox"/> 25 mg tab	<input type="checkbox"/> 100 mg tab	<input type="checkbox"/> 150 mg tab
<input type="checkbox"/> <b>TASIGNA</b>	<input type="checkbox"/> 150 mg cap	<input type="checkbox"/> 200 mg cap	
<input type="checkbox"/> <b>TEMOZOLOMIDE</b>	<input type="checkbox"/> 5 mg cap	<input type="checkbox"/> 20 mg cap	<input type="checkbox"/> 100 mg cap
	<input type="checkbox"/> 140 mg cap	<input type="checkbox"/> 180 mg cap	<input type="checkbox"/> 250 mg cap
Total daily dose based on BSA: _____ mg POI daily for _____ days off,			
repeat cycle every _____ days for _____ cycles.			
<input type="checkbox"/> <b>THALOMID</b>	<input type="checkbox"/> 50 mg cap	<input type="checkbox"/> 100 mg cap	
	<input type="checkbox"/> 150 mg cap	<input type="checkbox"/> 200 mg cap	
<input type="checkbox"/> <b>TYKERB</b>	<input type="checkbox"/> 250 mg tab		
<input type="checkbox"/> <b>VOTRIENT</b>	<input type="checkbox"/> 200 mg tab		
<input type="checkbox"/> <b>XELODA</b>	<input type="checkbox"/> 150 mg tab	<input type="checkbox"/> 500 mg tab	
<input type="checkbox"/> <b>XTANDI</b>	<input type="checkbox"/> 40 mg cap	<input type="checkbox"/> 160 mg (four 40 mg caps) po daily	
	<input type="checkbox"/> Alternate Dosage _____		
<input type="checkbox"/> <b>ZYTIGA</b>	<input type="checkbox"/> 250 mg tab; 4 times daily (1000 mg)		
	<input type="checkbox"/> In combination w/Prednisone 5mg tab BID		
	<input type="checkbox"/> Alternate Dosage _____		

**OTHER** \_\_\_\_\_  
Dosage: \_\_\_\_\_  
Sig: \_\_\_\_\_  
QTY: \_\_\_\_\_ Refills: \_\_\_\_\_

**ANTIEMETICS**  
 Chemo-induced N/V  Radiation-induced N/V  
 **ALOXI**  **EMEND**  **DOLASETRON**  
 **ONDANSETRON**  **GRANISETRON**  
 **PROCHLORPERAZINE**  
Dosage: \_\_\_\_\_  
QTY: \_\_\_\_\_ Refills: \_\_\_\_\_

**SUPPORTIVE AGENTS**  
 **NEUPOGEN**  **ARANESP**  
 **NEULASTA**  **PROCRIT**  **EPOGEN**  
Dosage: \_\_\_\_\_  
QTY: \_\_\_\_\_ Refills: \_\_\_\_\_

Prescriber's Name / Practice \_\_\_\_\_ Office Contact \_\_\_\_\_  
Address \_\_\_\_\_ Suite# \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ ZIP \_\_\_\_\_  
Phone \_\_\_\_\_ Fax \_\_\_\_\_ Email \_\_\_\_\_  
License# \_\_\_\_\_ NPI# \_\_\_\_\_ UPIN# \_\_\_\_\_ DEA# \_\_\_\_\_

Prescriber's Signature (signature required. NO STAMPS) \_\_\_\_\_ Date \_\_\_\_\_

*By signing this form and utilizing our services, you are authorizing Jersey Shore Pharmacy and its employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.*

**IMPORTANT NOTICE:** This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

© 2019 UpTrend Consulting & Creative LLC - All rights reserved.